Table 3 Demographic and clinical data of the study vitiligo patients with and without autoimmune and autoinflammatory disease (n = 294)

Age, years

35 (3–86)

36.50 (8–78)

< 0.001*

< 18

18–39

40–59

60–79

≥ 80

29 (13.6)

111 (51.9)

64 (29.9)

9 (4.2)

1 (0.5)

6 (7.5)

42 (52.5)

24 (30.0)

8 (10.0)

-

0.235

Sex

Male

Female

108 (50.5)

106 (49.5)

25 (31.3)

55 (68.8)

0.003*

Disease duration

8 (0.10–54)

11.50 (0.30–50)

0.001*

Age at vitiligo onset

24 (1–84)

20.50 (2–75)

0.331

Course of the disease

Stationary

Regressive

Progressive

50 (23.4)

14 (6.5)

150 (70.1)

17 (21.3)

7 (8.8)

56 (70)

0.774

Affected BSA, %

1–25

26–50

51–75

76–100

90 (42.1)

98 (45.8)

15 (7)

11 (5.1)

44 (55)

33 (41.3)

1 (1.3)

2 (2.5)

0.076

Distribution

Face or body

Face and body

192 (89.7)

22 (10.3)

76 (95)

4 (5)

0.175

Laterality

Unilateral/midline

Bilateral

170 (79.4)

44 (20.6)

71 (88.8)

9 (11.3)

0.065

Family history of vitiligo

44 (20.6)

18 (22.5)

0.717

Family history of AIIDs

42 (19.6)

32 (40)

< 0.001*

VIDA

+ 4

+ 3

+ 2

+ 1

0

-1

39 (18.2)

23 (10.7)

27 (12.6)

57 (26.6)

45 (21.0)

23 (10.7)

22 (27.5)

9 (11.3)

8 (10.0)

20 (25.0)

12 (15.0)

9 (11.3)

0.560

Treatment

No

95 (44.4)

46 (57.5)

0.149

Local

100 (46.7)

31 (38.8)

Systemic

11 (5.1)

1 (1.3)

Both local and systemic

8 (3.7)

2 (2.5)